Cidara Therapeutics, Inc.CDTXNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average, modest growth trend.
Left:
||||
Year-over-year research & development expense growth
Latest
43.16%
↑ 264% above average
Average (39q)
11.87%
Historical baseline
Range
High:277.13%
Low:-61.44%
CAGR
+3.4%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 43.16% |
| Q2 2025 | 0.88% |
| Q1 2025 | -47.52% |
| Q4 2024 | 277.13% |
| Q3 2024 | 86.71% |
| Q2 2024 | 12.47% |
| Q1 2024 | -61.44% |
| Q4 2023 | 47.81% |
| Q3 2023 | 19.97% |
| Q2 2023 | -54.12% |
| Q1 2023 | -5.93% |
| Q4 2022 | 0.08% |
| Q3 2022 | 31.37% |
| Q2 2022 | -24.35% |
| Q1 2022 | 6.06% |
| Q4 2021 | -7.28% |
| Q3 2021 | 15.72% |
| Q2 2021 | 11.81% |
| Q1 2021 | -24.99% |
| Q4 2020 | 29.96% |
| Q3 2020 | -7.80% |
| Q2 2020 | 35.69% |
| Q1 2020 | 13.11% |
| Q4 2019 | -0.08% |
| Q3 2019 | 7.04% |
| Q2 2019 | -15.20% |
| Q1 2019 | -2.89% |
| Q4 2018 | 15.68% |
| Q3 2018 | -2.93% |
| Q2 2018 | -11.97% |
| Q1 2018 | 29.02% |
| Q4 2017 | 11.69% |
| Q3 2017 | -30.57% |
| Q2 2017 | 28.78% |
| Q1 2017 | -9.43% |
| Q4 2016 | 29.57% |
| Q3 2016 | 3.05% |
| Q2 2016 | 17.83% |
| Q1 2016 | -4.96% |
| Q4 2015 | 11.79% |